184 related articles for article (PubMed ID: 21271218)
21. Mechanism of action for the cytotoxic effects of the nitric oxide prodrug JS-K in murine erythroleukemia cells.
Kaczmarek MZ; Holland RJ; Lavanier SA; Troxler JA; Fesenkova VI; Hanson CA; Cmarik JL; Saavedra JE; Keefer LK; Ruscetti SK
Leuk Res; 2014 Mar; 38(3):377-82. PubMed ID: 24461365
[TBL] [Abstract][Full Text] [Related]
22. JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.
Kiziltepe T; Hideshima T; Ishitsuka K; Ocio EM; Raje N; Catley L; Li CQ; Trudel LJ; Yasui H; Vallet S; Kutok JL; Chauhan D; Mitsiades CS; Saavedra JE; Wogan GN; Keefer LK; Shami PJ; Anderson KC
Blood; 2007 Jul; 110(2):709-18. PubMed ID: 17384201
[TBL] [Abstract][Full Text] [Related]
23. JS-K, a nitric oxide prodrug, induces cytochrome c release and caspase activation in HL-60 myeloid leukemia cells.
Udupi V; Yu M; Malaviya S; Saavedra JE; Shami PJ
Leuk Res; 2006 Oct; 30(10):1279-83. PubMed ID: 16439016
[TBL] [Abstract][Full Text] [Related]
24. A reactive oxygen species activation mechanism contributes to JS-K-induced apoptosis in human bladder cancer cells.
Qiu M; Chen L; Tan G; Ke L; Zhang S; Chen H; Liu J
Sci Rep; 2015 Oct; 5():15104. PubMed ID: 26458509
[TBL] [Abstract][Full Text] [Related]
25. Protein phosphatase 2A mediates JS-K-induced apoptosis by affecting Bcl-2 family proteins in human hepatocellular carcinoma HepG2 cells.
Liu L; Huang Z; Chen J; Wang J; Wang S
J Cell Biochem; 2018 Aug; 119(8):6633-6643. PubMed ID: 29693750
[TBL] [Abstract][Full Text] [Related]
26. Identification of targets of JS-K against HBV-positive human hepatocellular carcinoma HepG2.2.15 cells with iTRAQ proteomics.
Liu Z; Xu Y; Zhang W; Gao X; Luo G; Song H; Liu J; Wang H
Sci Rep; 2021 May; 11(1):10381. PubMed ID: 34001947
[TBL] [Abstract][Full Text] [Related]
27. Resveratrol mediated cell death in cigarette smoke transformed breast epithelial cells is through induction of p21Waf1/Cip1 and inhibition of long patch base excision repair pathway.
Mohapatra P; Satapathy SR; Das D; Siddharth S; Choudhuri T; Kundu CN
Toxicol Appl Pharmacol; 2014 Mar; 275(3):221-31. PubMed ID: 24467951
[TBL] [Abstract][Full Text] [Related]
28. Structural modifications modulate stability of glutathione-activated arylated diazeniumdiolate prodrugs.
Nandurdikar RS; Maciag AE; Holland RJ; Cao Z; Shami PJ; Anderson LM; Keefer LK; Saavedra JE
Bioorg Med Chem; 2012 May; 20(9):3094-9. PubMed ID: 22480849
[TBL] [Abstract][Full Text] [Related]
29. Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme.
Günzle J; Osterberg N; Saavedra JE; Weyerbrock A
Cell Death Dis; 2016 Sep; 7(9):e2349. PubMed ID: 27584787
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of piperazine and homopiperazine analogues of JS-K, an anti-cancer lead compound.
Nandurdikar RS; Maciag AE; Citro ML; Shami PJ; Keefer LK; Saavedra JE; Chakrapani H
Bioorg Med Chem Lett; 2009 May; 19(10):2760-2. PubMed ID: 19364650
[TBL] [Abstract][Full Text] [Related]
31. JS-K as a nitric oxide donor induces apoptosis via the ROS/Ca
Huang Z; Liu L; Chen J; Cao M; Wang J
Biomed Pharmacother; 2018 Nov; 107():1385-1392. PubMed ID: 30257354
[TBL] [Abstract][Full Text] [Related]
32. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.
Weidensteiner C; Reichardt W; Shami PJ; Saavedra JE; Keefer LK; Baumer B; Werres A; Jasinski R; Osterberg N; Weyerbrock A
Nitric Oxide; 2013 Apr; 30():17-25. PubMed ID: 23370169
[TBL] [Abstract][Full Text] [Related]
33. JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.
Kiziltepe T; Anderson KC; Kutok JL; Jia L; Boucher KM; Saavedra JE; Keefer LK; Shami PJ
J Pharm Pharmacol; 2010 Jan; 62(1):145-51. PubMed ID: 20723011
[TBL] [Abstract][Full Text] [Related]
34. Hybrid molecule from O2-(2,4-dinitrophenyl)diazeniumdiolate and oleanolic acid: a glutathione S-transferase π-activated nitric oxide prodrug with selective anti-human hepatocellular carcinoma activity and improved stability.
Fu J; Liu L; Huang Z; Lai Y; Ji H; Peng S; Tian J; Zhang Y
J Med Chem; 2013 Jun; 56(11):4641-55. PubMed ID: 23617697
[TBL] [Abstract][Full Text] [Related]
35. JS-K, a novel non-ionic diazeniumdiolate derivative, inhibits Hep 3B hepatoma cell growth and induces c-Jun phosphorylation via multiple MAP kinase pathways.
Ren Z; Kar S; Wang Z; Wang M; Saavedra JE; Carr BI
J Cell Physiol; 2003 Dec; 197(3):426-34. PubMed ID: 14566972
[TBL] [Abstract][Full Text] [Related]
36. Salinomycin efficiency assessment in non-tumor (HB4a) and tumor (MCF-7) human breast cells.
Niwa AM; D Epiro GF; Marques LA; Semprebon SC; Sartori D; Ribeiro LR; Mantovani MS
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):557-71. PubMed ID: 26932586
[TBL] [Abstract][Full Text] [Related]
37. MMP-9 increases HER2/neu expression and alters apoptosis levels in human mammary epithelial cells (HMEC).
Fatunmbi M; Shelton J; Aronica SM
Breast Cancer Res Treat; 2012 Sep; 135(2):519-30. PubMed ID: 22878890
[TBL] [Abstract][Full Text] [Related]
38. Role of human glutathione transferases in biotransformation of the nitric oxide prodrug JS-K.
Sjödin B; Mannervik B
Sci Rep; 2021 Oct; 11(1):20765. PubMed ID: 34675290
[TBL] [Abstract][Full Text] [Related]
39. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines.
Ramachandran C; Rodriguez S; Ramachandran R; Raveendran Nair PK; Fonseca H; Khatib Z; Escalon E; Melnick SJ
Anticancer Res; 2005; 25(5):3293-302. PubMed ID: 16101141
[TBL] [Abstract][Full Text] [Related]
40. The nitric oxide prodrug JS-K and its structural analogues as cancer therapeutic agents.
Maciag AE; Saavedra JE; Chakrapani H
Anticancer Agents Med Chem; 2009 Sep; 9(7):798-803. PubMed ID: 19538173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
